Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Status of PCSK9 Monoclonal Antibodies in Australia.
Scherer DJ, Nelson AJ, O'Brien R, Kostner KM, Hare DL, Colquhoun DM, Barter PJ, Aylward P, Nicholls SJ, Watts GF. Scherer DJ, et al. Among authors: aylward p. Heart Lung Circ. 2019 Oct;28(10):1571-1579. doi: 10.1016/j.hlc.2019.04.014. Epub 2019 May 8. Heart Lung Circ. 2019. PMID: 31104887 Review.
Intensive LDL Reduction Post Acute Coronary Syndromes: A Catalyst for Improved Outcomes.
Kostner K, Nicholls S, Amerena J, Brown A, Cooper M, Hammett C, O'Brien R, Kritharides L, Hare DL, Watts GF, Aylward P, Kostner K, Nicholls S, Amerena J, Brown A, Cooper M, Hammett C, O'Brien R, Kritharides L, Hare DL, Watts GF, Aylward P. Kostner K, et al. Among authors: aylward p. Heart Lung Circ. 2016 Nov;25(11):1051-1054. doi: 10.1016/j.hlc.2016.09.005. Heart Lung Circ. 2016. PMID: 27725093 No abstract available.
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Hagström E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Hagström E, et al. Circulation. 2022 Aug 30;146(9):657-672. doi: 10.1161/CIRCULATIONAHA.121.057807. Epub 2022 Jun 30. Circulation. 2022. PMID: 35770629 Free PMC article. Clinical Trial.
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, López-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD, Gabriel Steg P; ODYSSEY Outcomes Committees and Investigators. Schwartz GG, et al. J Am Coll Cardiol. 2021 Aug 3;78(5):421-433. doi: 10.1016/j.jacc.2021.04.102. J Am Coll Cardiol. 2021. PMID: 34325831 Free PMC article. Clinical Trial.
Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long-Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study.
West M, Kirby A, Stewart RA, Blankenberg S, Sullivan D, White HD, Hunt D, Marschner I, Janus E, Kritharides L, Watts GF, Simes J, Tonkin AM; LIPID Study Group *. West M, et al. J Am Heart Assoc. 2022 Mar;11(5):e020745. doi: 10.1161/JAHA.121.020745. Epub 2022 Feb 18. J Am Heart Assoc. 2022. PMID: 35179040 Free PMC article.
National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016.
Chew DP, Scott IA, Cullen L, French JK, Briffa TG, Tideman PA, Woodruffe S, Kerr A, Branagan M, Aylward PE; NHFA/CSANZ ACS Guideline 2016 Executive Working Group:. Chew DP, et al. Among authors: aylward pe. Heart Lung Circ. 2016 Sep;25(9):895-951. doi: 10.1016/j.hlc.2016.06.789. Epub 2016 Jun 16. Heart Lung Circ. 2016. PMID: 27476580 Free article. Review. No abstract available.
Corrigendum to 'National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016' Heart Lung and Circulation volume 25, (2016) 898 - 952.
Chew DP, Scott IA, Cullen L, French JK, Briffa TG, Tideman PA, Woodruffe S, Kerr A, Branagan M, Aylward PEG; NHFA/CSANZ ACS Guideline 2016 Executive Working Group. Chew DP, et al. Among authors: aylward peg. Heart Lung Circ. 2017 Oct;26(10):1117. doi: 10.1016/j.hlc.2017.08.004. Heart Lung Circ. 2017. PMID: 28867028 Free article.
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.
Szarek M, Bittner VA, Aylward P, Baccara-Dinet M, Bhatt DL, Diaz R, Fras Z, Goodman SG, Halvorsen S, Harrington RA, Jukema JW, Moriarty PM, Pordy R, Ray KK, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG, Schwartz GG; ODYSSEY OUTCOMES Investigators. Szarek M, et al. Among authors: aylward p. Eur Heart J. 2020 Nov 21;41(44):4245-4255. doi: 10.1093/eurheartj/ehaa649. Eur Heart J. 2020. PMID: 33051646 Free PMC article. Clinical Trial.
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE–TIMI 58 Investigators. Wiviott SD, et al. N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10. N Engl J Med. 2019. PMID: 30415602 Clinical Trial.
296 results